<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        19-887-17
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2017
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        PURINETHOL 50MG TAB
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        MERCAPTOPURINE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        50
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        25
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Tablet Container
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        60
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        do not store above 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        328.75
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="EXCELLA GmbH &amp; Co.KG " />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            EXCELLA GmbH & Co.KG 
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 354]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            SAUDI INTERNATIONAL TRADING COMPANY LTD (SITCO)
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            ASPEN PHARMA TRADING LIMITED (APTL)
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        L01BB02
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>1.&nbsp; What Puri-Nethol is and what it is used for</strong></p><p>Puri-Nethol tablets contain the active substance called 6-mercaptopurine. 6-mercaptopurine belongs to a group of medicines called cytotoxics (also called chemotherapy) and works by reducing the number of new blood cells your body makes.</p><p>Puri-Nethol is used to treat cancer of the blood (leukaemia) in adults, adolescents and children. This is a fast-growing disease which increases the number of new white blood cells. These new white blood cells are immature (not fully formed) and unable to grow and work properly. They therefore cannot fight infections and may cause bleeding.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>2.&nbsp; What you need to know before you take Puri-Nethol Do not take Puri-Nethol:</strong></p><p>If you are allergic to 6-mercaptopurine or any of the other ingredients of this medicine (see section 6).</p><p>Do not get vaccinated with yellow fever vaccine whilst you are taking Puri-Nethol because it may be fatal.</p><p><strong>Warnings and precautions</strong></p><p>Talk to your doctor or pharmacist or nurse before taking Puri-Nethol if:</p><ul><li>If you have been vaccinated with yellow fever vaccine.</li><li>You take Puri- Nethol, you should not have a live organism vaccine (for example; flu vaccine, measles vaccine, BCG vaccine, etc.) until advised it is safe to do so by your doctor. This is because some vaccines may give you an infection if you receive them while you are taking Puri-Nethol</li><li>You have kidney or liver function or liver<s> </s>problems, as your doctor will need to check that they are working properly.</li><li>You have a condition where your body produces too little of the enzyme called TPMT (thiopurine methyltransferase) as your doctor may need to adjust the dose.</li><li>You are planning to have a baby. This applies to both men and women. Puri-nethol may harm your sperm or eggs (see &lsquo;Pregnancy, breast-feeding and fertility&rsquo; below).</li><li>If you have a mutation in your NUDT15 gene, you may have a higher risk of developing low levels of white cells in your blood compared to other patients. This may cause you to get infections. The mutation may also put you at a higher risk of losing your hair. Patients of Asian descent may be particularly at risk If you have an allergy to a medicine called azathioprine (also used to treat cancer)</li><li>If you have, or have not, had chicken pox, shingles or hepatitis B (a liver disease caused by a virus).</li><li>You have a genetic condition called Lesch-Nyhan Syndrome</li></ul><p>If you are receiving immunosuppressive therapy, taking Puri-Nethol could put you at greater risk of:</p><ul><li>Tumours, including skin cancer. Therefore, when taking Puri-Nethol, avoid excessive exposure to sunlight, wear protective clothing and use protective sunscreen with a high protection factor.</li><li>lymphoproliferative disorders:</li></ul><p>-&nbsp; Treatment with Puri-Nethol increases your risk of getting a type of cancer called lymphoproliferative disorder. With treatment regimen containing multiple immunosuppressants (including thiopurines), this may lead to death.</p><p>-&nbsp; A combination of multiple immunosuppressants, given concomitantly increases the risk of disorders of the lymph system due to a viral infection (Epstein-Barr virus (EBV) &ndash; associated lymphoproliferative disorders).</p><p>Taking Puri-Nethol could put you at greater risk of:</p><ul><li>developing a serious condition called Macrophage Activation Syndrome (excessive activation of white blood cells associated with inflammation), which usually occurs in people who have certain types of arthritis.</li><li>Some patients with inflammatory bowel disease who have received 6-mercaptopurine have developed a rare and aggressive type of cancer called Hepatosplenic T-cell Lymphoma (see section 4, Possible side effects).</li></ul><p>The use of Puri-nethol for the treatment of inflammatory bowel disease (IBD) is an unlicensed indication</p><p><strong>Blood tests</strong></p><ul><li>Treatment with Puri-Nethol may affect your bone marrow. This means you may have a reduced number of white blood cells, platelets and (less commonly) red blood cells in your blood. Your doctor will carry out blood tests daily when you are at the beginning of your treatment (induction) and at least weekly when you are further along into your treatment (maintenance). This is in order to monitor the levels of these cells in your blood. If you stop treatment early enough, your blood cells will return to normal.</li><li>Your doctor may also perform genetic testing (i.e. looking at your TPMT and/or NUDT15 genes) before or during your treatment to determine if your response to this medication may be affected by your genetics.</li></ul><p><strong>Liver function</strong></p><ul><li>Puri-Nethol is toxic to your liver. Therefore, your doctor will carry out weekly liver function tests when you are taking Puri-Nethol. If you already have liver disease, or if you are taking other medications which may affect your liver, your doctor will carry out more frequent tests. If you notice the whites of your eyes or your skin turn yellow (jaundice) tell your doctor immediately as you may need to stop your treatment immediately.</li></ul><p><strong>Pellagra</strong></p><ul><li>Talk to your doctor immediately if you experience diarrhoea, localized pigmented rash (dermatitis), decline in your memory, reasoning or other thinking skills (dementia) as these symptoms may suggest vitamin B3 deficiency (nicotinic acid deficiency/pellagra). Your doctor will likely prescribe vitamin supplements (niacin/nicotinamide) to help treat this condition.</li></ul><p><strong>Infections</strong></p><ul><li>When you are taking Puri-Nethol you may be more likely to get infections caused by viruses, bacteria and fungus and your reaction to these infections may be more severe than people who are not being taking Puri-Nethol. If you think you have an infection, talk to your doctor immediately.</li></ul><p><strong>Children and adolescents</strong></p><p>Low blood sugar has sometimes been seen in children, mainly in children under the age of six or with a low body mass index. Talk to your child&acute;s doctor if this happens.</p><p>If you are not sure if any of the above applies to you, talk to your doctor or pharmacist before taking Puri-Nethol.</p><p><strong>Other medicines and Puri-Nethol</strong></p><p>Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.</p><p>In particular, tell your doctor or pharmacist if you are taking any of the following:</p><ul><li>Ribavirin (used to treat viruses)</li><li>Other cytotoxic medicines (chemotherapy &ndash; used to treat cancer)</li><li>Allopurinol, thiopurinol, oxipurinol or febuxostat (used to treat gout)</li><li>Olsalazine or Mesalazine (used to treat a Crohn&rsquo;s Disease and bowel problem called ulcerative colitis)</li><li>Sulfasalazine (used to treat rheumatoid arthritis or ulcerative colitis)</li><li>Methotrexate (used to treat rheumatoid arthritis or severe psoriasis)</li><li>Infliximab (used to treat Crohn&rsquo;s Disease and ulcerative colitis, rheumatoid arthritis, ankylosing spondylitis or severe psoriasis)</li><li>Warfarin or acenocoumarol (used to &lsquo;thin&rsquo; the blood)</li><li>Anti-epileptic medicines such as phenytoin, carbamazepine. Blood levels of anti-epileptic medicines may need to be monitored and doses adjusted if necessary.</li></ul><p><strong>Having vaccines while you are taking Puri-Nethol</strong></p><p>If you are going to have a vaccination speak to your doctor or nurse before you have it. If you take Puri-Nethol, you should not have a live vaccine (like polio, measles, mumps and rubella) until advised it is safe to do so by your doctor. This is because some vaccines may give you an infection if you have them whilst you are taking Puri-Nethol.</p><p><strong>Puri-Nethol with food and drink</strong></p><p>You can take Puri-Nethol with food or on an empty stomach but the choice of method should be consistent from day to day. You should take your medicine at least 1 hour before or 2 hours after having milk or dairy products.</p><p><strong>Pregnancy, breastfeeding and fertility</strong></p><p>Do not take Puri-nethol if you are planning to have a baby without first speaking to your doctor for advice. This applies to both men and women. Puri-nethol may harm your sperm or eggs. Reliable contraception must be used to avoid pregnancy whilst you or your partner are taking Puri-nethol. Both men and women should continue to use effective contraception from 3 to 6 months after stopping treatment. If you are already pregnant, you must talk to your doctor before taking Puri-nethol. Puri- nethol should not be handled by women who are or planning to be pregnant or breast-feeding. Do not breast-feed while taking Puri-nethol. Ask your doctor, pharmacist or midwife for advice.</p><p><strong>Driving and using machines</strong></p><p>It is not expected that Puri-Nethol will affect your ability to drive or use machines, but no studies have been done to confirm this.</p><p><strong>Puri-Nethol tablets contain lactose</strong></p><p>If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before you take Puri-Nethol tablets.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>3.&nbsp; How to take Puri-Nethol</strong></p><ul><li>Puri-nethol treatment must be initiated and monitored under the supervision of a physician experienced in treating cancers of the blood.</li><li>Puri-nethol is a hazrdouse drug. Need caution when handling Puri-nethol to minimize risk of exposure.</li><li>Personal not taking Puri-nethol should not exposed to it.</li><li>Tablets should be swallowed whole.</li><li>The tablets should not be broken or crushed.</li><li>When you take Puri-Nethol, your doctor will take regular blood tests. This is to check the number and type of cells in your blood, and to ensure your liver is working correctly</li><li>Your doctor may also ask for other blood and urine tests to monitor how your kidneys are working and to measure uric acid levels. Uric acid is a natural substance made in your body and levels of uric acid can rise while you are taking Puri-Nethol. High levels of uric acid may damage your kidneys</li><li>Your doctor may sometimes change your dose of Puri-Nethol as a result of these tests.</li></ul><p>Always take Puri-Nethol exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure. It is important to take your medicine at the right times. The label on your pack will tell you how many tablets to take and how often to take them. If the label does not say or if you are not sure, ask your doctor, nurse or pharmacist.</p><p>The usual dose for adults and children is 2.5 mg per kilogram of your body weight each day (or alternatively 50 to 75 mg per m2 of your body surface area each day). Your doctor will calculate and adjust your dose based on your body weight, results of your blood tests, whether or not you are taking other chemotherapy medicines and your kidney and liver function.</p><ul><li>Do not chew the tablets. If you or your caregiver does handle broken tablets, wash the hands immediately.</li></ul><p>You can take your medicine with food or on an empty stomach but the choice of method should be consistent from day to day. You should take your medicine at least 1 hour before or 2 hours after having milk or dairy products.</p><p><strong>If you take more Puri-Nethol than you should</strong></p><p>If you take more Puri-Nethol than you should, you may feel sick, vomit or have diarrhoea. Tell your doctor immediately or go to a hospital immediately straight away. Take the medicine pack with you.</p><p><strong>If you forget to take Puri-Nethol</strong></p><p>Tell your doctor. Do not take a double dose to make up for a forgotten dose.</p><p><strong>If you stop taking Puri-Nethol</strong></p><p>Do not stop taking your medicine unless your doctor tells you to or you may get a relapse of your condition</p><p>If you have any further questions on the use of this medicine, ask your doctor, nurse or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>4.&nbsp; Possible side effects</strong></p><p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p>If you get any of the following, talk to your specialist doctor straight away or seek urgent medical advice:</p><ul><li>Allergic reaction the signs may include</li><li>Skin rashes</li><li>High temperature</li><li>Joint pain</li><li>Swollen face</li><li>Any signs of fever or infection (sore throat, sore mouth or urinary problems)</li><li>Any unexpected bruising or bleeding, as this could mean that too few blood cells of a particular type are being produced</li><li>If you suddenly feel unwell (even with a normal temperature) and have abdominal pain and sickness, as this could be a sign of an inflamed pancreas</li><li>Any yellowing of the whites of the eyes or skin (jaundice)</li><li>If you have diarrhea</li></ul><p>Talk to your doctor if you have any of the following side effects, which may also happen with this medicine:</p><p><strong>Very common (affects more than 1 in 10 people)</strong></p><ul><li>a drop in the number of white blood cells and platelets (may show up in blood tests)</li></ul><p><strong>Common (affects less than 1 in 10 people)</strong></p><ul><li>Nausea (you feel sick) or vomiting (being sick)</li><li>&nbsp;Liver damage&nbsp;</li><li>this may show up in blood tests</li><li>A drop in red blood cells which may make you tired, weak or breathless (called anemia)</li><li>Loss of appetite</li><li>Diarrhea</li><li>Inflammation of the mouth (stomatitis)</li></ul><p><strong>Uncommon (affects 1 in 100 people)</strong></p><ul><li>Loss of appetite</li><li>Mouth ulcers</li><li>Inflammation of the pancreas (pancreatitis)</li><li>Joint pain</li><li>Skin rash</li><li>Fever</li><li>permanent damage to the liver (hepatic necrosis)</li><li>Bacterial and viral infections, infections associated with neutropenia</li></ul><p><strong>Rare (affects less than 1 in 1,000 people)</strong></p><ul><li>Hair loss</li><li>In men: temporary low sperm count</li><li>Swollen face</li><li>Various types of cancers including blood, lymph and skin cancers</li></ul><p><strong>Very rare (affect 1 in 10,000 people)</strong></p><ul><li>A different type of leukaemia to that being treated</li><li>Cancer of the spleen and liver (in patients with a condition called Inflammatory Bowel Disease)</li><li>Ulcers in the intestines; symptoms may include abdominal pain and bleeding</li><li><strong>&nbsp;Other side effects (the frequency is unknown)</strong></li><li><strong>a rare type of cancer (hepatosplenic T-cell lymphoma), (see section 2, Warnings and Precautions).</strong></li><li>Increased sensitivity to sunlight and UV light causing skin reactions</li><li>Skin nodules (erythema nodosum)</li></ul><p><strong>Additional side effects in children</strong></p><p>Low blood sugar levels (sweating more than usual, nausea, dizziness, confusion, etc.) have been reported in some children receiving Puri-Nethol; the frequency is not known. However, most of the children were under the age of six years old and had a low body weight.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>5.&nbsp; How to store Puri-Nethol</strong></p><ul><li>Keep this medicine out of the sight and reach of children.</li><li>Do not use this medicine after the expiry date which is stated on the pack after &lsquo;Exp&rsquo;.</li><li>Do not store above 30&deg;C. Protect from light and moisture.</li><li><em>Puri-nethol </em>is a cytotoxic drug, need caution when handling to minimize risk of exposure.</li><li>The tablets should not be divided, broken or crushed.</li><li>Transport and store medicine in the original container or blister.</li><li>For medication administration, use gloves and wash hands thoroughly before and after. If gloves are not worn, tip tablets and from their container/blister pack directly into a disposable medicine cup.</li><li>People who are not taking Puri-nethol should not be exposed to it.</li><li>Caution should be observed in handling broken or crushed tablets Avoid direct contact of the <em>Puri-nethol </em>with skin or mucous membranes. If such contact occurs, wash thoroughly with soap and water, rinse eyes thoroughly with sterile water, or plain water if sterile water is unavailable.</li><li>Pregnant should avoid exposure to <em>Puri-nethol </em>tablets.</li><li>Family members use gloves when handling laundry or cleaning within or around toilets.</li><li>Close the lid before flushing the toilet and flush twice after each use by patient, for 48 hours after receiving chemotherapy. If available, use separate bathroom from family members.</li><li>Conduct double washing of linens and wash them separately from other family laundry.</li><li>If your doctor tells you to stop taking the medication, or if it expired. Do not throw away via wastewater or household waste. Ask your pharmacist how to throw away medicine you no longer use, or return it to your pharmacist, who will destroy them according to disposal of dangerous substance guidelines.</li><li>These measures will help protect environment.</li><li>Only keep the medicine if your doctor tells you to.</li></ul>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>What Puri-Nethol contains</strong></p><p>The active substance is 6-mercaptopurine. Each tablet contains 50 mg of 6-mercaptopurine. The other ingredients are Lactose Monohydrate, maize starch, Modified Maize Starch, stearic acid, Purified Water, and magnesium stearate.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                What Puri-Nethol looks like and contents of the pack
Puri-Nethol tablets are a pale yellow colour and are marked with PT above the score and 50 below the score.
Your Puri-Nethol tablets are in bottles of 25 tablets.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Marketing Authorisation Holder and Manufacturer</strong></p><p><strong>Marketing Authorisation holder:</strong></p><p>Aspen Pharma Trading Limited 3016 Lake Drive,</p><p>Citywest Business Campus,</p><p>Dublin 24, Ireland</p><p><strong>Manufacturer:</strong></p><p>&nbsp;EXCELLA GmbH &amp; Co. KG,</p><p>&nbsp;90537 Feucht, Germany.</p><p><u><strong>OR</strong></u></p><p><strong>Manufacturer:</strong></p><p>Aspen SA Operations (Pty) Ltd.,</p><p>Corner of Fairclough Road and Gibaud Road,</p><p>Korsten, Gqeberha, 6020,</p><p>Republic of South Africa.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflet was last revised in {December/2023}, Version number {7}
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL"><strong>1 - ما عقار &quot;بيوري-نيثول&quot;، وفيم يُستخدم ؟</strong></p><p dir="RTL">يحتوي عقار &quot;بيوري-نيثول&quot; أقراص على المادة الفعالة التي يطلق عليها اسم &quot; 6 - ميركابتوبيورين&quot;. وينتمي &quot; 6 - ميركابتوبيورين&quot; إلى مجموعة الأدوية التي يُطْلَق عليه اسم &quot;سامٌّة للخَلاَيا&quot; (كما يطلق عليها أيضًا اسم&quot;العلاج الكيميائي&quot;)؛ والتي يتمثل عملها في الحد من عدد خلايا الدم الجديدة التي يكونها الجسم .</p><p>ويُسْتَعْمَل &quot;بيوري - نيثول&quot; في علاج حالات سرطان الدم (اللوكيميا) في المرضى البالغين، والمراهقين وكذلك الأطفال. وهو داء سريع النمو يعمل على زيادة عدد خلايا الدم البيضاء الجديدة، وتكون هذه الخلايا غير ناضجة (غير مكتملة التكوين) وغير قادرة على النمو والعمل بشكل سليم، لذك لا يمكنها مكافحة العدوى وقد تسبب النزيف.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>2 - ما المعلومات التي يحتاج المريض إلى معرفتها، قبل تناول دواء &quot;بيوري-نيثول &quot;</strong></p><p dir="RTL"><strong>يجب على المريض عدم تناول عقار &quot;بيوري-نيثول&quot; في الحالات التالية</strong><strong>:</strong></p><p dir="RTL">إذا كان الشخص يعاني من فرط الحساسية تجاه &quot; 6 - ميركابتوبيورين&quot;،أو تجاه أي من المكونات الأخرى الداخلة في تكوين هذا الدواء ( يرجى مراجعة القسم 6) .</p><p dir="RTL">تجنب تلقي لقاح الحمى الصفراء خلال فترة العلاج بدواء بوري نيثول لأن ذلك قد يؤدي إلى الوفاة.</p><p dir="RTL"><strong>التحذيرات والاحتياطات</strong></p><p dir="RTL">يجب على المريض التحدث مع الطبيب أو الصيدلي أو الممرضة قبل تناول &quot;بيوري-نيثول&quot; في الحالات التالية :</p><ul dir="rtl"><li>إذا كنت قد تلقيت لقاح الحمى الصفراء.</li><li>في حالة تلقي المريض مؤخرًا، أو إذا كان من المقرر أن يتلقى أحد اللقاحات (التطعيم). يجب على المريض- في حالة تناول &quot;بيوري - نيثول&quot; عدم تلقي لقاحات الكائنات الحية (مثل لِقاحُ الإِنْفلوَنْزَا، ولِقاحُ الحَصْبَة، ولِقاحُ &quot;بي سي جي&quot;، وما إلى ذلك)؛ وذلك إلى أن يتم إبلاغة من قِبَل الطبيب بإمكانية تلقي اللِقاحْ. وذلك لأنه من الممكن أن تتسبب بعض اللقاحات في إحداث العدوى؛ وذلك في حالة تلقي تلك اللقاحات في أثناء تناول &quot;بيوري- نيثول &quot;</li><li>إذا كان المريض يعاني من هبوط في وظائف الكلى أو الكبد، أو إذا كان يعاني من أي مشاكل بالكبد ، وفي حال ذلك سيتولى طبيبك إجراء فحوصات للتأكد من سلامتهما.</li><li>إذا كان المريض يعاني من الحالة الجينية (الوراثية) التي يطلق عليها اسم نقص الإنزيم ناقل ميثيل الثيوبيورين(تي.بيه.إم.تي) ، فقد يحتاج طبيبك إلى تعديل جرعتك.</li><li>إذا كنت تخطط/ين للحمل ، وهذا ينطبق على الرجال والنساء على حد سواء. فقد يؤثر &quot;بيوري- نيثول&quot; سلبا على الحيوانات المنوية أو البويضات (راجع/ي قسم &quot;الحمل والرضاعة الطبيعية والخصوبة&quot; بالأسفل).</li><li>يمكن أن يزداد خطر تعرض المريض للإصابة بانخفاض مستويات كُريات الدم البيضاء مقارنة بالمرضى الآخرين؛ وذلك إذا كان لدى المريض طَفْرَة في الجين &quot;إن.يو.دي.تي 15 &quot;. ومن الممكن أن يتسبب ذلك في تعرض المريض للإصابة بأنواع العدوى. ومن الممكن أن تتسبب تلك الطفرة في زيادة المخاطر المتعلقة بفقد الشعر. ومن الممكن أن يتعرض المرضى الذين ينحدرون من أصول أسيوية للخطر بشكل خاص؛ وذلك إذا كانوا يعانون من الحساسية تجاه الدواء الذي يطلق عليه اسم &quot;إزاثيوبرين&quot; (والذي يستعمل أيضًا في علاج السرطان)</li><li>إذا كان المريض يعاني من مشاكل في الكلى.</li><li>إذا كان قد تعرض - أو لم يكن قد تعرض - للإصابة بالجُدَرِي، أو الهِرْبِسٌ أو التهاب الكبد من النوع &quot;ب&quot; (أحد أمراض الكبد الناتجة عن الإصابة بأحد الفيروسات).</li><li>إذا كان المريض يعاني من الحالة الجينية (الوراثية) التي يطلق عليها اسم مُتَلاَزِمَةُ &quot;ليش- نايهان&quot;</li></ul><p dir="RTL">إذا كان المريض يتلقى علاجًا مُثَبِّطًا للمناعة؛ حيث من الممكن في هذه الحالة - أن يتسبب تناول &quot;بيوري- نيثول&quot; في زيادة خطر التعرض للإصابة بما يلي :</p><ul dir="rtl"><li>الأورام، بما في ذلك سرطان الجلد. ومن ثم فإنه يجب عند تناول &quot;بيوري- نيثول&quot; تجنب التعرض المفرط لأشعة الشمس، وارتداء ملابس واقية من أشعة الشمس؛ وذلك بالإضافة إلى استعمال مستحضرات الوقاية من الشمس، ذات معامل الحماية المرتفع.</li><li>&nbsp;الاضطرابات التَّكاثُرِيَّةُ اللِّمْفِيَّة (الليمفاوية) :</li></ul><p dir="RTL">- تزداد مخاطر التعرض للإصابة بما يُسَمى سرطان الاضطرابات التَّكاثُرِيَّةُ اللِّمْفِيَّة؛ وذلك في حالة العلاج باستعمال &quot;بيوري</p><p dir="RTL">- نيثول&quot;. وقد تؤدي تلك المخاطر- مع استعمال أنظمة العلاج التي تحتوي على مُثَبِّطات المناعة المتعددة (بما في ذلك الثيوبورينات) - إلى الوفاة .</p><p dir="RTL">- تزداد مخاطر التعرض للإصابة باضطرابات الجهاز الليمفاوي، نتيجة لأحد الالتهابات الفيروسية (فيروس إيبِشتاين بار- (إي.بي.في) - المصاحبة للاضطرابات التَّكاثُرِيَّةُ اللِّمْفِيَّة)؛ وذلك في حالة العلاج باستعمال توليفة متزامنة من مُثَبِّطات المناعة المتعددة.</p><p dir="RTL">قد يؤدي تناول المريض لعقار &quot;بيوري- نيثول&quot;، إلى زيادة تعرضه للمخاطر التالية :</p><ul dir="rtl"><li>الإصابة بحالة خطيرة يُطْلَق عليها اسم متلازمة تَنْشيطُ البَلاعِم (زيادة نشاط خلايا الدم البيضاء، المصحوبة بالالتهاب)؛ وهو ما يحدث عادة مع الأشخاص الذين يعانون من أنواع معينة من التهاب المفاصل.</li><li>أصيب بعض مرضى التهابات الأمعاء الذين تلقوا مادة 6 - ميركابتوبيورين بنوع نادر وشديد الخطورة من السرطان يُسمى الورم اللمفاوي التائي الكبدي الطحالي (انظر القسم [4]، الآثار الجانبية المحتملة).</li></ul><p dir="RTL">&nbsp;</p><p dir="RTL">لا يُصرَّح باستخدام بوري نيثول لعلاج أمراض التهابات الأمعاء (IBD)</p><p dir="RTL"><strong>فحوصات الدم</strong></p><ul dir="rtl"><li>يمكن أن يؤثر العلاج باستعمال &quot;بيوري- نيثول&quot; على نخاع العظم. وهو ما يعني إمكانية تعرض المريض لنقص في عدد خلايا الدم البيضاء، وفي الصفيحات الدموية وكذلك في عدد خلايا الدم الحمراء، وإن كانت الأخيرة أقل شيوعًا. سوف يقوم الطبيب - عند بدء العلاج التحفيزي- بإجراء اختبارات الدم بشكل يومي؛ كما سوف يقوم الطبيب- عند الاستمرار في علاج المداومة بإجراء تلك الاختبارات بشكل أسبوعي على الأقل. ويتم إجراء هذه الاختبارت بغرض متابعة مستويات خلايا الدم لدى المريض. سوف تعود مستويات كرات الدم إلى مستوياتها الطبيعية؛ وذلك في حالة إيقاف المريض للعلاج في وقت مبكر.</li></ul><p dir="RTL"><strong>الاختبارات المعملية الأخرى</strong></p><ul dir="rtl"><li>وقد يقوم الطبيب أيضًا-قبل البدء في العلاج أو في أثناء العلاج- بإجراء بعض الاختبارات الجينية (بمعنى فحص الجين &quot;تي.بيه.إم.تي&quot; و/أو الجين &quot;إن. يو.دي.تي 15 &quot;) ؛ وذلك بغرض تحديد ما إذا كانت استجابة المريض للدواء سوف تتأثر بالخصائص الوراثية للجينات.</li></ul><p dir="RTL"><strong>وظائف الكبد</strong></p><ul dir="rtl"><li>لعقار &quot;بيوري- نيثول&quot; تأثيرًا سامًا على الكبد. ولذلك سوف يقوم الطبيب بإجراء اختبارات وظائف الكبد بشكل أسبوعي؛ وذلك عند العلاج باستعمال &quot;بيوري- نيثول&quot;. سوف يقوم الطبيب بإجراء تلك الاختبارات بشكل أكثر تواترًا؛ وذلك إذا كان المريض يعاني بالفعل من أمراض الكبد، أو إذا كان يتناول أى من الأدوية الأخرى التي يمكن أن تؤثر على الكبد. يجب على المريض إبلاغ الطبيب فورًا؛ وذلك في حالة ملاحظة تغير لون العينين أو الجلد إلى اللون الأصفر (أحد أعراض مرض اليرقان)؛ حيث قد يتطلب الأمر إيقاف العلاج فورًا .</li></ul><p dir="RTL"><strong>البيلاغرا</strong></p><ul dir="rtl"><li>استشر طبيبك على الفور إذا كنت تعاني من الإسهال أو الطفح الجلدي المصحوب بتصبغ موضعي (التهاب الجلد) أو تدهور في الذاكرة أو التمييز المنطقي أو غيرهما من المهارات العقلية الأخرى (الخرف)، حيث قد تشير هذه الأعراض إلى نقص فيتامين ب 3 (نقص حمض النيكوتينيك/البيلاغرا)، وعلى الأرجح سيصف لك طبيبك مكملات تحتوي على الفيتامينات (النياسين/النيكوتيناميد) للمساعدة في علاج هذه الحالة.</li></ul><p dir="RTL"><strong>أنواع العدوى</strong></p><ul dir="rtl"><li>قد يكون المريض- عند استعمال&quot;بيوري- نيثول&quot; أكثر تعرضًا للإصابة بالعدوى الناتجة عن الفيروسات، والبكتيريا والفطريات؛ كما قد يكون رد فعل جسم المريض تجاه هذه الأنواع من العدوى أكثر شدة، وذلك مقارنة بالأشخاص الذين لا يستعملون &quot;بيوري- نيثول&quot;. ولذلك فإنه يجب على المريض التحدث مع الطبيب، إذا كان يعتقد بأنه يعاني من أي من أنواع العدوى.</li></ul><p dir="RTL"><strong>الأطفال والمراهقين</strong></p><p dir="RTL">يُلاحظ أحيانًا انخفاض سكر الدم عند الأطفال، خاصةً الأطفال الذين تقل أعمارهم عن ست سنوات أو اتسموا بانخفاض مؤشر كتلة الجسم، فاستشر الطبيب الخاص بطفلك في حالة حدوث ذلك.</p><p dir="RTL">يجب على المريض التحدث مع الطبيب أو الصيدلي قبل تناول عقار &quot;بيور ي- نيثول&quot;؛ وذلك إذا لم يكن متأكدًا مما إذا كان أي مما سبق ينطبق عليه.</p><p dir="RTL"><strong>استعمال الأدوية الأخرى مع عقار &quot;بيوري-نيثول</strong><strong> &quot;</strong></p><p dir="RTL">يجب على المريض إبلاغ الطبيب أو الصيدلي، إذا كان يتناول، أو إذا كان قد تناول مؤخراً، أو إذا كان من المحتمل أن يتناول أي أدوية أخرى .</p><p dir="RTL">ويجب على المريض إبلاغ الطبيب، أو الصيدلي؛ وذلك إذا كان يتناول أي من الأدوية التالية على وجه الخصوص :</p><ul dir="rtl"><li>&nbsp; &quot;ريبافيرين&quot; (يستعمل لعلاج الفيروسات)</li><li>الأدوية الأخرى السامَّة للخلية (العلاج الكيميائي- الذي يستعمل لعلاج السرطان )</li><li>&quot;ألوبيورينول&quot;، أو &quot;أوكسيبورينول&quot; أو &quot;ثيوبيورينول &quot; (تستعمل لعلاج حالات النقرس)</li><li>&quot;أولسالازين&quot; أو &quot;ميسالازين (يستعمل لعلاج داء &raquo;كرون &laquo;بالإضافة إلى علاج التهاب القولون التقرحي)</li><li>&quot;سلفاسالازين&quot; (يستعمل لعلاج التهاب المفاصل الروماتويدي، وكذلك علاج التهاب القولون التقرحي)</li><li>&quot;ميثوتركسات&quot; (يستعمل لعلاج التهاب المفاصل الروماتويدي، وكذلك علاج حالات الصدفية الشديدة)</li><li>&quot;إنفليكسيماب&quot; (يستعمل لعلاج متلازمة &quot;كرون&quot;، وعلاج التهاب القولون التقرحي، والتهاب المفاصل الروماتويدي، والْتِهابُ الفَقارِ الرُّوماتويديِّ بالإضافة إلى علاج حالات الصدفية الشديدة)</li><li>&quot;وارفارين&quot; أو &quot;أسينوكومارول&quot; (يستعمل لتخفيف لزوجة الدم)</li><li>مضادات الصرع مثل فينيتوين وكاربامازيبين، وقد يلزم متابعة مستويات مضادات الصرع في الدم وتعديل الجرعات إذا لزم الأمر.</li></ul><p dir="RTL"><strong>تلقي المريض للقاحات في أثناء العلاج باستعمال &quot;بيوري-نيثول</strong><strong> &quot;</strong></p><p dir="RTL">يجب على المريض التحدث مع الطبيب أو الممرضة؛ وذلك إذا كان على وشك تلقي أي من التطعيمات. يجب على المريض- في حالة تناول &quot;بيوري- نيثول&quot; - عدم تلقي لقاحات الكائنات الحية (مثل لقاح شلل الأطفال والحصبة والنكاف والحصبة الألمانية) ؛ وذلك إلى أن يتم إبلاغة من قِبَل الطبيب بإمكانية تلقي اللِقاحْ. وذلك لإمكانية أن تتسبب بعض أنواع اللقاحات في إحداث العدوى؛ وذلك في حالة تلقي تلك اللقاحات في أثناء تناول &quot;بيوري- نيثول &quot;</p><p dir="RTL"><strong>تناول عقار &quot;بيوري -نيثول&quot; مع الطعام والشراب</strong></p><p dir="RTL">يمكن للمريض تناول عقار &quot;بيوري-نيثول&quot; مع الطعام أو على معدة فارغة؛ وإن كانت تجب المواظبة على تناول العقار بنفس الطريقة دائمًا. يجب تناول الدواء قبل ساعة واحدة على الأقل من تناول الحليب أو أي من منتجات الألبان، أو بعد ساعتين على الأقل من تناول الحليب أو أي من منتجات الألبان.</p><p dir="RTL"><strong>الحمل والإرضاع والخصوبة</strong></p><p dir="RTL">لا يجب تناول بيوري- نيثول في حالة التخطيط للإنجاب بدون التحدث أولاً إلى الطبيب للاستشارة. وهذا ينطبق على كل من الرجال والنساء. فقد يسبب بيوري- نيثول ضرراً للحيوانات المنوية أو البويضات. ويجب استخدام وسيلة منع حمل موثوقة لتجنب حدوث الحمل إذا كنت أنت أو زوجك/ زوجتك تستخدم بيوري- نيثول. ينبغي على كل من الرجال والسيدات الاستمرار في استخدام وسيلة منع حمل فعالة لمدة لا تقل عن 3 إلى 6 أشهر بعد إيقاف العلاج. إذا كنتِ حاملاً بالفعل، فلابد أن تتحدثي مع طبيبك قبل تناول بيوري- نيثول. ينبغي على السيدات الحوامل أو اللاتي يخططن للحمل أو يرضعن رضاعة الطبيعية عدم التعامل مع بيوري- نيثول. امتنعى عن الرضاعة الطبيعية أثناء تناول بيوري- نيثول. اطلبي المشورة من طبيبك، أو الصيدلي أو القابلة .</p><p dir="RTL"><strong>قيادة السيارات واستخدام الماكينات</strong></p><p dir="RTL">من غير المتوقع أن يكون لعقار &quot;بيوري- نيثول&quot; أي تأثير فيما يتعلق بالقدرة على قيادة المركبات أو استعمال الماكينات؛ وإن لم يتم إجراء أي من الدراسات اللازمة لتأكيد ذلك.</p><p dir="RTL"><strong>تحتوي أقراص &quot;بيوري-نيثول&quot; على اللاكتوز</strong></p><p dir="RTL">يجب على المريض الاتصال بالطبيب قبل تناول أقراص &quot;بيوري- نيثول&quot;؛ وذلك إذا كان المريض على عِلْم من خلال طبيب، بأنه يعاني من عدم تقبل بعض أنواع السكر.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>3</strong><strong> - </strong><strong>كيفية تناول أقراص &quot;بيوري-نيثول</strong><strong> &quot;</strong></p><ul dir="rtl"><li>يجب بدء العلاج بيوري- نيثول ومراقبته تحت إشراف طبيب خبير في إدارة الأمراض الخبيثة.</li><li>بيوري- نيثول دواء خطير. ينبغي توخي الحذر عند التعامل مع بيوري- نيثول للحد من مخاطر التعرض .</li><li>الشخص الذي لا يتناول بيوري- نيثول يجب ألا يتعرض له .</li><li>يجب ابتلاع الأقراص كاملة.</li><li>يجب ألا تُكسر الأقراص أو تسحق .</li><li>سوف يقوم الطبيب- عند وصف العلاج باستعمال &quot;بيوري- نيثول &quot;- بإجراء اختبارات للدم بشكل منتظم. وذلك بغرض التحقق من عدد وحالة خلايا الدم لدى المريض؛ وكذلك للتأكد من أداء الكبد لوظيفته بالشكل الصحيح .</li><li>قد يطلب الطبيب أيضًا إجراء بعض الاختبارات الأخرى للبول والدم؛ وذلك بغرض متابعة حالة الكلى، وأيضًا لقياس مستويات حمض اليوريك. حمض اليوريك عبارة عن مادة طبيعية تتكون في الجسم؛ ومن الممكن أن ترتفع مستويات حمض اليوريك في أثناء العلاج باستعمال &quot;بيوري- نيثول&quot;. ومن الممكن أن تتسبب المستويات المرتفعة من حمض اليوريك في إتلاف الكليتين.</li><li>قد يقوم الطبيب- في بعض الأحيان- بتغيير الجرعة من عقار &quot;بيوري- نيثول&quot; وذلك وفقًا لنتيجة الاختبارات التي تُجْرى .</li></ul><p dir="RTL">يجب الالتزام- دائمًا وبدقة- بتعليمات الطبيب أو الصيدلي وذلك فيما يتعلق باستعمال &quot;بيوري- نيثول&quot;. ويجب على المريض مراجعة الطبيب أو الصيدلي؛ وذلك في حالة عدم التأكد من أي أمر يتعلق بالدواء. من المهم التزام المريض لتناول الدواء في المواعيد الصحيحة. يمكن للمريض- من خلال المُلْصَق الموجود على العبوة- معرفة عدد الأقراص المطلوب تناولها، وكذلك عدد مرات التناول. يجب على المريض التحدث مع الطبيب أو الممرضة أو الصيدلي؛ وذلك في حالة عدم احتواء المُلْصَق على مثل تلك المعلومات، أو في حالة عدم تأكد المريض من أي من المعلومات .</p><p dir="RTL">الجرعة اليومية المعتادة بالنسبة للبالغين والأطفال هي 2.5 ملغ لكل كيلو غرام من وزن الجسم (أو جرعة يومية تتراوح ما بين 50 - 75 ملغ لكل متر<sup>2</sup> من مساحة سطح الجسم). وسوف يقوم الطبيب بحساب وضبط الجرعة العلاجية؛ وذلك على أساس وزن جسم المريض، ونتائج اختبارات الدم، وما إذا كان المريض يتناول أي من أدوية العلاج الكيميائي الأخرى، بالإضافة إلى حالة وظائف الكلى والكبد لدى المريض .</p><ul dir="rtl"><li>حيث يجب على المريض تجنب مضغ الأقراص. إذا قام أي من المريض أو مقدم الرعاية الطبية بتداول الأقراص المكسورة؛ فإنه يجب غسل اليدين فور الانتهاء من ذلك.</li></ul><p dir="RTL">يمكن للمريض تناول &quot;بيوري- نيثول&quot; مع الطعام أو على معدة فارغة؛ وإن كانت تجب المواظبة على تناول العقار بنفس الطريقة دائمًا. يجب تناول الدواء قبل ساعة واحدة على الأقل من تناول الحليب أو أي من منتجات الألبان، أو بعد ساعتين على الأقل من تناول الحليب أو أي من منتجات الألبان .</p><p dir="RTL"><strong>في حالة تناول المريض لجرعة أكبر مما يجب من أقراص &quot;بيوري-نيثول</strong><strong> &quot;</strong></p><p dir="RTL">في حالة تناول جرعة أكبر مما يجب من أقراص &quot;بيوري- نيثول &quot; ، قد تشعر بالغثيان أو القيء أو الإسهال. يجب على المريض إبلاغ الطبيب فورًا- أو التوجه إلى المستشفى على الفور- وذلك ، كما يجب على المريض اصطحاب عبوة الدواء معه .</p><p dir="RTL"><strong>في حالة نسيان تناول جرعة من أقراص &quot;بيوري-نيثول</strong><strong> &quot;</strong></p><p dir="RTL">يجب على المريض إبلاغ الطبيب بذلك. <strong>ويجب على المريض عدم تناول جرعة مزدوجة من الدواء، بغرض تعويض الجرعة المنسية</strong> .</p><p dir="RTL"><strong>في حالة توقف المريض عن تناول أقراص&quot;بيوري-نيثول</strong><strong> &quot;</strong></p><p dir="RTL">لا تتوقف عن تناول الدواء الخاص بك إلا إذا أخبرك الطبيب بذلك، وإلا فقد تحدث انتكاسة لحالتك الصحية يجب على المريض التواصل مع الطبيب، أو مع الممرضة أو الصيدلي؛ وذلك إذا كانت لديه أية أسئلة أخرى تتعلق باستعمال هذا الدواء .</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>4-<strong> </strong>الآثار الجانبية ممكنة الحدوث</strong></p><p dir="RTL">يمكن لهذا الدواء- كما هو الحال بالنسبة لجميع الأدوية الأخرى- أن يتسبب في إحداث بعض الآثار الجانبية؛ وذلك على الرغم من عدم تعرض جميع الأشخاص لمثل تلك الأعراض الجانبية .</p><p dir="RTL">يجب على المريض التحدث مع الطبيب المتخصص فورًا، أو طلب النصيحة الطبية العاجلة؛ وذلك في حالة التعرض لأي من الأمور التالية:</p><ul dir="rtl"><li>رد فعل تحسسي، وقد تتضمن أعراضه ما يلي:</li><li>الطفح الجلدي.</li><li>ارتفاع درجة الحرارة</li><li>آلام المفاصل</li><li>تورم الوجه</li><li>أي علامات دالة على الحمى أو العدوى (التهاب الحلق أو قرحة الفم أو مشاكل بولية)</li><li>الظهور المفاجئ للكدمات أو النزيف المفاجئ، حيث يمكن أن يعني هذا قلة إنتاج أحد أنواع خلايا الدم</li><li>في حال الشعور بالاعتلال المفاجئ (حتى إذا كانت درجة حرارتك طبيعية) وبآلام حادة في البطن وغثيان، قد يكون ذلك مؤشرًا على التهاب البنكرياس.</li><li>اصفرار أي من أجزاء بياض العين أو الجلد (اليرقان)</li><li>في حال الإصابة بالإسهال</li></ul><p dir="RTL">يجب على المريض إبلاغ الطبيب إذا لاحظ ظهور أي من الأعراض التالية، والتي يمكن أن تحدث أيضًا مع هذا الدواء :</p><p dir="RTL"><strong>الآثار الجانبية الشائعة جدًا (تؤثر على أكثر من 1 من كل 10 أشخاص)</strong></p><ul dir="rtl"><li>انخفاض في عدد خلايا الدم البيضاء والصفائح الدموية (قد يظهر في فحوصات الدم)</li></ul><p dir="RTL"><strong>الآثار الجانبية الشائعة (تؤثر على أقل من 1 من كل 10 أشخاص)</strong></p><ul dir="rtl"><li>غثيان (الشعور بالتقيؤ) أو قيء</li><li>تليف الكبد&nbsp;</li><li>قد يظهر ذلك في فحوصات الدم</li><li>انخفاض في خلايا الدم الحمراء مما قد يصيبك بالتعب أو الوهن أو ضيق التنفس (حالة تُعرَف بفقر الدم&quot;أنيميا&quot;)</li><li>فقدان الشهية</li><li>&nbsp;الإسهال</li><li>&nbsp;التهاب الفم</li></ul><p dir="RTL"><strong>الآثار الجانبية غير الشائعة ( تؤثر على 1 من كل 100 شخص):</strong></p><ul dir="rtl"><li>فقدان الشهية</li><li>تقرحات الفم</li><li>التهاب البنكرياس</li><li>آلام المفاصل</li><li>الطفح الجلدي</li><li>الحمى</li><li>التليف الكبدي الدائم (النخر الكبدي)</li><li>العداوى البكتيرية والفيروسية، العداوى المرتبطة بقلة العدلات</li></ul><p dir="RTL"><strong>الآثار الجانبية النادرة (تؤثر على أقل من 1 من كل 1000 شخص)</strong></p><ul dir="rtl"><li>تساقط الشعر</li><li>لدى الرجال: انخفاض مؤقت في عدد الحيوانات المنوية</li><li>تورم الوجه</li><li>&nbsp;أنواع مختلفة من السرطانات بما في ذلك سرطان الدم والغدد اللمفاوية والجلد</li></ul><p dir="RTL"><strong>الآثار الجانبية النادرة جداً (التي قد تؤثر في شخص واحد من بين كل 10,000 شخص)</strong></p><ul dir="rtl"><li>نوع من سرطان الدم (اللوكيميا) بخلاف النوع الذي يتم علاجه.</li><li>سرطان الطحال والكبد (بالنسبة للمرضى الذين يعانون من حالة تُسَمِّى مرض التهاب الأمعاء)</li><li>قُرَح الأمعاء؛ ويمكن أن تشمل الأعراض الشعور بألم في البطن بالإضافة إلى التعرض للنزيف</li></ul><p dir="RTL"><strong>الآثار الجانبية الأخرى (غير معروفة النسبة) </strong></p><ul dir="rtl"><li>نوع نادر من السرطان (ليمفوما الخلايا التائية الكبدية الطحالية)، (راجع&nbsp; القسم [2]، التحذيرات والاحتياطات).</li><li>&nbsp;زيادة الحساسية تجاه ضوء الشمس وكذلك الأشعة فوق البنفسجية</li><li>&nbsp;العقد الجلدية (الحمامى العقدية)</li></ul><p dir="RTL"><strong>الآثار الجانبية الإضافية بالنسبة للأطفال</strong></p><p dir="RTL">وردت تقارير بنسب غير معروفة أو محددة بخصوص بعض حالات التعرض لانخفاض مستويات سكر الدم (التعرق بشكل أكثر من الطبيعي، والغثيان، والدوخة، وعدم التركيز وما إلى ذلك)؛ وذلك بالنسبة لبعض الأطفال ممن يتلقون العلاج باستعمال &quot;بيوري- نيثول&quot;، وقد كانت أعمار معظم الأطفال أقل من السادسة، كما كانت أوزان أجسامهم أقل من الطبيعي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>5-</strong><strong> </strong><strong>كيفية تخزين أقراص &quot;بيوري-نيثول</strong><strong> &quot;</strong></p><ul dir="rtl"><li>يجب حفظ هذا الدواء بعيدًا عن رؤية ومتناول الأطفال .</li><li>يجب عدم استخدام هذا الدواء بعد تاريخ الصلاحية المدون على العبوة بعد الاختصارExp.</li><li>يجب عدم تخزين أقراص &quot;بيوري- نيثول&quot; في درجة حرارة تتجاوز 30 درجة مئوية. تُحْفَظ الزجاجة مُحْكَمَة الغلق .</li><li>بيوري- نيثول دواء خطير، وينبغي توخي الحذر عند التعامل معه للحد من مخاطر التعرض .</li><li>يجب ألا تُقسم الأقراص، أو تُكسر أو تُسحق.</li><li>يُنقل الدواء ويُخزن في الشريط أو الحاوية الأصلية .</li><li>لتقديم الدواء، تُستخدم القفازات وتُغسل اليدين جيداً قبل تقديم الدواء وبعده. في حالة عدم ارتداء القفازات، تقلب الأقراص من عبوتها/ الشريط مباشرة في كوب طبي يمكن التخلص منه.</li><li>الأشخاص الذين لا يتناولون بيوري-نيثول يجب ألا يتعرضوا له .</li><li>يجب توخي الحذر عند التعامل مع أقراص مكسورة أو مسحوقة. تجنب التلامس المباشر للبيوري- نيثول مع الجلد أو الأغشية المخاطية. في حالة حدوث التلامس، يُغسل موضع التلامس جيداً بالماء والصابون، وتُشطف العينين جيداً بماء معقم، أو ماء عادي في حالة عدم توفر الماء المعقم.</li><li>ينبغي على السيدات الحوامل تجنب التعرض لأقراص بيوري- نيثول.</li><li>يجب على أفراد الأسرة استخدام القفازات عند التعامل مع الغسيل أو التنظيف داخل المراحيض أو حولها .</li><li>&nbsp;أغلق الغطاء قبل شطف المرحاض بالدفق واشطفه مرتين بعد كل استخدام من قبل المريض، وذلك لمدة 48 ساعة بعد تلقي العلاج الكيميائي. عند التوفر، استخدم حماما منفصلاً عن الحمام الذي يستخدمه أفراد الأسرة .</li><li>&nbsp;يجب غسل البياضات غسلاً مزدوجا وتغسل بشكل منفصل عن غسيل الأسرة الآخر .</li><li>إذا أخبرك الطبيب بالتوقف عن تناول الدواء، أو انتهت صلاحيته. لا تتخلص من الدواء في ماء الصرف الصحي أو مع المخلفات المنزلية. اسأل الصيدلي عن كيفية التخلص من الأدوية التي لم تعد تستخدمها، أو أعدها إلى الصيدلي الذي سيقوم بإتلافها وفقا لإرشادات التخلص من المواد الخطرة.</li><li>&nbsp;ستساعد هذه الإجراءات في الحفاظ على البيئة.</li><li>&nbsp;احتفظ بالدواء فقط إذا أخبرك طبيبك بذلك.</li></ul>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>ما المواد التي تحتوي عليها أقراص &quot;بيوري-نيثول</strong><strong> &quot;</strong></p><p dir="RTL">المادة الفعالة &quot; 6 - ميركابتوبيورين&quot;. يحتوي كل قرص على 50 ملغ من &quot; 6 - ميركابتوبيورين&quot;. أما المكونات الأخرى فهي مونوهيدرات اللاكتوز، ونشا الذرة، ونشا الذرة المعدل، و حمض الستياريك ، والماء المقطر، بالإضافة إلى سترات المغنسيوم.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">أقراص &quot;بيوري- نيثول&quot; هي أقراص ذات لون أصفر شاحب، كما تحتوي الأقراص على الرمز PT فوق خط و 50 تحت خط</p><p dir="RTL">أقراص &quot;بيوري- نيثول&quot; متوفرة في عبوات تحتوي على 25 قرص .</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>اسم وعنوان مالك رخصة التسويق والمصنع الشركة صاحبة تفويض التسويق:</strong></p><p dir="RTL"><strong>مالك رخصة التسويق</strong><br />أسبن فارما تريدينج المحدودة، 3016 ليك درايف، سيتي ويست<br />بزنس كامبوس، دوبلن 24 ، أيرلندا</p><p dir="RTL"><strong>الشركة المصنعة</strong><strong> :</strong></p><p dir="RTL">إكسيلا وشركاؤه المحدودة، طريق نورنرجر 12 ، 90537 فويشت، ألمانيا</p><p dir="RTL"><u><strong>أو</strong></u></p><p dir="RTL"><strong>الشركة المصنعة</strong><strong> :</strong></p><p dir="RTL">أسبن إس أي أوبريشنز (بي تي واي) المحدودة</p><p dir="RTL">زاوية إلتقاء طريق فيرلوق مع طريق قيباود ،</p><p dir="RTL">كورستن، جكيبرها، 6020 ،</p><p dir="RTL">جمهورية جنوب إفريقيا</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            تمت مراجعة هذه النشرة في {ديسمبر/ 2023}، رقم النسخة {7}
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Puri-Nethol 50 mg tablets
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                6-mercaptopurine.

Each tablet contains 50 mg of the active substance 6-mercaptopurine.

Excipients with known effect:

Lactose

For the full list of excipients, see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                
Tablets

Pale yellow, round tablets, biconvex, scored on one side, engraved PT above the score and 50 below the score and plain on the other side.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>6- mercaptopurine is indicated for the treatment of acute leukaemia in adults, adolescents and children. It may be utilised in:</p><p>-&nbsp;&nbsp; Acute lymphoblastic leukaemia (ALL);</p><p>-&nbsp;&nbsp; Acute promyelocytic leukaemia (APL)/Acute myeloid leukaemia M3 (AML M3)).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>General:</u></p><p>Puri-nethol treatment must be initiated and monitored under the supervision of a physician experienced in hematology.</p><p><strong><u>Posology</u>&nbsp;</strong></p><p>The dose is governed by cautiously monitored haematotoxicity and the dose should be carefully adjusted to suit the individual patient in accordance with the employed treatment protocol.</p><p>Depending on phase of treatment, starting or target doses should be lower in patients with reduced or absent Thiopurine Methyl Transferase (TPMT) enzyme activity (see section 4.4).</p><p>6-mercaptopurine treatment should be supervised by a physician or other healthcare professional experienced in the management of patients with ALL and APL (AML M3).<strong>&nbsp;</strong></p><p>For adults and children the usual dose is 2.5 mg/kg bodyweight per day, or 50 to 75 mg/m <sup>2</sup> body surface area per day, but the dose and duration of administration depend on the nature and dosage of other cytotoxic agents given in conjunction with 6-mercaptopurine.</p><p>The dosage should be carefully adjusted to suit the individual patient.</p><p>6- mercaptopurine has been used in various combination therapy schedules for acute leukaemia and the literature and current treatment guidelines should be consulted for details.</p><p>Studies carried out in children with acute lymphoblastic leukaemia suggested that administration of 6- mercaptopurine in the evening lowered the risk of relapse compared with morning administration.</p><p><u>Switching between tablet and oral suspension and vice versa </u></p><p><u>An oral suspension of 6-mercaptopurine is also available. The 6-mecaptopurine oral suspension and tablet are not bioequivalent with respect to peak plasma concentration, and therefore intensified haematological monitoring of the patient is advised on switching formulations (see section 5.2).</u></p><p><u>Method of administration</u></p><p><u>6 mercaptopurine may be taken with food or on an empty stomach, but patients should standardise the method of administration. The dose should not be taken with milk or dairy products (see section 4.5). 6 mercaptopurine should be taken at least 1 hour before or 2 hours after milk or dairy products. </u></p><p>&nbsp;</p><p><u>Special populations </u></p><ul><li><strong>Elderly</strong></li></ul><p>It is advisable to monitor renal and hepatic function in these patients, and if there is impairment, consideration should be given to reducing the 6-mercaptopurine dosage.</p><ul><li><strong>Renal impairment</strong></li></ul><p>Since 6-mercaptopurine pharmacokinetics has not been formally studied in renal impairment, no specific dose recommendations can be given. Since impaired renal function may result in slower elimination of mercaptopurine and its metabolites and therefore a greater cumulative effect, consideration should be given to reduced starting doses in patients with impaired renal function. Patients should be closely monitored for dose related adverse reactions.</p><ul><li><strong>Hepatic impairment</strong></li></ul><p>Since 6-mercaptopurine pharmacokinetics has not been formally studied in hepatic impairment, no specific dose recommendations can be given. Since there is a potential for reduced elimination of mercaptopurine, consideration should be given to reduced starting doses in patients with impaired hepatic function. Patients should be closely monitored for dose related adverse reactions (see sections 4.4 and 5.2)</p><ul><li><strong>Combination with xanthine oxidase inhibitors</strong></li></ul><p>When the xanthine oxidase inhibitors, such as allopurinol, oxipurinol or thiopurinol and 6- mercaptopurine are administered concomitantly it is essential that only 25 % of the usual dose of 6- mercaptopurine is given since these agents decrease the rate of catabolism of 6-mercaptopurine. Concomitant administration of other xanthine oxidase inhibitors, such as febuxostat, should be avoided (see section 4.5 Interaction with other medicinal products and other forms of interactions).</p><ul><li><strong>TPMT-deficient patients</strong></li></ul><p>6-Mercaptopurine is metabolised by the polymorphic TPMT enzyme. Patients with little or no inherited thiopurine S-methyltransferase (TPMT) activity are at increased risk for severe 6-mercaptopurine toxicity from conventional doses of 6-mercaptopurine and generally require substantial dose reduction. The optimal starting dose for homozygous deficient patients has not been established. <u>TPMT genotyping or phenotyping can be used to identify patients with absent or reduced TPMT activity. TPMT testing cannot substitute for haematological monitoring in patients receiving mercaptopurine </u>(see section 4.4 and section 5.2).</p><ul><li><strong>&nbsp;Patients with NUDT15 variant</strong></li></ul><p>Patients with inherited mutated NUDT15 gene are at increased risk for severe thiopurine toxicity, such as early leukopenia and alopecia, from conventional doses of thiopurine therapy and generally require substantial dose reduction. Patients of Asian ethnicity are particularly at risk, due to the increased frequency of the mutation in this population. The optimal starting dose for heterozygous or homozygous deficient patients has not been established.</p><p>Genotypic and phenotypic testing of NUDT15 variants should be considered before initiating thiopurine therapy in all patients (including paediatric patients) to reduce the risk of thiopurine-related severe leukocytopenia and alopecia, especially in Asian populations (see section 5.2).</p><p><u>Method of Administration:</u></p><ul><li>Puri-nethol is a cytotoxic agent. Follow applicable special handling and disposal procedures (see section 6.6).</li></ul><p>&nbsp;</p><ul><li>Tablets should be swallowed whole.</li></ul><p>&nbsp;</p><ul><li>The tablets should not be broken or crushed, if possible. This might produce powder that can contaminate workplace surfaces.</li></ul><p>&nbsp;</p><ul><li>If tablet must be cut or crushed, this should be done by a professional trained personal experienced in safe handling of hazardous drugs using an appropriate equipment and safety procedures.</li></ul>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance or to any of the excipients listed in section 6.1 

In view of the seriousness of the indications there are no other absolute contra-indications.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em>6-mercaptopurine is an active cytotoxic agent and should be use only under the direction of physician experienced in the administration of such agents.</em></p><p><u>Cytotoxicity and haematological monitoring</u></p><p><u>Treatment with 6-mercaptopurine causes bone marrow suppression leading to leucopenia and thrombocytopenia and, less frequently, to anaemia. Careful monitoring of haematological parameters should be conducted during therapy. The leucocyte and platelet counts continue to fall after treatment is stopped, so at the first sign of an abnormally large fall in the counts, treatment should be interrupted immediately. Bone marrow suppression is reversible if 6-mercaptopurine is withdrawn early enough.</u></p><p><u>There are individuals with an inherited deficiency of the TPMT enzyme activity who are very sensitive to the myelosuppressive effect of 6-mercaptopurine and prone to developing rapid bone marrow depression following the initiation of treatment with 6-mercaptopurine. This problem could be exacerbated by coadministration with active substances that inhibit TPMT, such as olsalazine, mesalazine or sulfasalazine. Some laboratories offer testing for TPMT deficiency, although these tests have not been shown to identify all patients at risk of severe toxicity. Therefore close monitoring of blood counts is necessary. Substantial dose reductions are generally required for homozygous-TPMT deficiency patients to avoid the development of life threatening bone marrow suppression.</u></p><p><u>A possible association between decreased TPMT activity and secondary leukaemias and myelodysplasia has been reported in individuals receiving 6-mercaptopurine in combination with other cytotoxics (see section 4.8).</u></p><p><u>Immunosuppression</u></p><p>Immunisation using a live organism vaccine has the potential to cause infection in immunocompromised hosts. Therefore, immunisations with live organism vaccines are not recommended.</p><p>Co-administration of ribavirin and 6-mercaptopurine is not advised. Ribavirin may reduce efficacy and increase toxicity of 6-mercaptopurine (see section 4.5 Interaction with other medicinal products and other forms of interactions).</p><p>During remission induction in acute myelogenous leukaemia, the patient may frequently have to survive a period of relative bone marrow aplasia and it is important that adequate supportive facilities are available.</p><p>The dosage of 6-mercaptopurine may need to be reduced when this agent is combined with other medicinal products whose primary or secondary toxicity is myelosuppression (see Section 4.5 Interaction with other medicinal products and other forms of interactions: Myelosuppressive agents).</p><p><u>Hepatotoxicity</u></p><p>6-mercaptopurine is hepatotoxic and liver function tests should be monitored weekly during treatment.</p><p>Gamma glutamyl transferase (GGT) levels in plasma may be particularly predictive of withdrawal due to hepatotoxicity. More frequent monitoring may be advisable in those with pre- existing liver disease or receiving other potentially hepatotoxic therapy. The patient should be instructed to discontinue 6-mercaptopurine immediately if jaundice becomes apparent (see section 4.8).</p><p><u>Renal toxicity </u></p><p>During remission induction when rapid cell lysis is occurring, uric acid levels in blood and urine should be monitored as hyperuricaemia and/or hyperuricosuria may develop, with the risk of uric acid nephropathy. <u>Hydration and urine alkalinisation may minimize potential renal complications.</u></p><p><u>Caution is advised during the administration of 6-mercaptopurine in patients with renal impairment and/or hepatic impairment (see section 4.2 and section 5.2).</u></p><p><u>&nbsp;Pancreatitis in off-label treatment of patients with inflammatory bowel disease</u></p><p><u>Pancreatitis has been reported to occur at a frequency of &ge; 1/100 to &lt; 1/10 (&ldquo;common&rdquo;) in patients treated for the unlicensed indication inflammatory bowel disease.</u></p><p><u>&nbsp;Mutagenicity and carcinogenicity</u></p><p><u>Patients receiving immunosuppressive therapy, including mercaptopurine, are at an increased risk of developing lymphoproliferative disorders and other malignancies, notably skin cancers (melanoma and non-melanoma), sarcomas (Kaposi&#39;s and non-Kaposi&#39;s) and uterine cervical cancer in situ. The increased risk appears to be related to the degree and duration of immunosuppression. It has been reported that discontinuation of immunosuppression may provide partial regression of the lymphoproliferative disorder.</u></p><p><u>&nbsp;A treatment regimen containing multiple immunosuppressants (including thiopurines) should therefore be used with caution as this could lead to lymphoproliferative disorders, some with reported fatalities. A combination of multiple immunosuppressants, given concomitantly increases the risk of Epstein-Barr virus (EBV)-associated lymphoproliferative disorders.</u></p><p><u>&nbsp;Increases in chromosomal aberrations were observed in the peripheral lymphocytes of leukaemic patients, in a renal cell carcinoma patient who received an unstated dose of 6 mercaptopurine and in patients with chronic renal disease treated at doses of 0.4 - 1.0 mg/kg/day.</u></p><p><u>&nbsp;In view of its action on cellular deoxyribonucleic acid (DNA) 6-mercaptopurine is potentially carcinogenic and consideration should be given to the theoretical risk of carcinogenesis with this treatment.</u></p><p><u>&nbsp;Two cases have been documented of the occurrence of acute non-lymphatic leukaemia in patients who received 6 mercaptopurine, in combination with other medicinal products, for non-neoplastic disorders.&nbsp; </u></p><p><u>&nbsp;A single case has been reported where a patient was treated for pyoderma gangrenosum with 6 mercaptopurine and later developed acute non-lymphatic leukaemia, but it is not clear whether this was part of the natural history of the disease or if the 6 mercaptopurine played a causative role.</u></p><p><u>&nbsp;A patient with Hodgkin&rsquo;s disease treated with 6 mercaptopurine and multiple additional cytotoxic agents developed acute myelogenous leukaemia. </u></p><p><u>Hepatosplenic T-cell lymphoma has been reported in patients with inflammatory bowel disease* treated with azathioprine (the prodrug to 6-mercaptopurine) or 6-mercaptopurine, either with or without concomitant treatment with anti-TNF alpha antibody. This rare type of T cell lymphoma has an aggressive disease course and is usually fatal (see also section 4.8).</u></p><p><u>&nbsp;*inflammatory bowel disease (IBD) is an unlicensed indication.</u></p><p><u>&nbsp;Twelve and a half years after 6 mercaptopurine treatment for myasthenia gravis, a female patient developed chronic myeloid leukaemia.</u></p><p><u>&nbsp;</u><strong><u>Macrophage activation syndrome</u></strong></p><p><u>Macrophage activation syndrome (MAS) is a known, life-threatening disorder that may develop in patients with autoimmune conditions, in particular with inflammatory bowel disease (IBD) (unlicensed indication), and there could potentially be an increased susceptibility for developing the condition with the use of mercaptopurine. If MAS occurs, or is suspected, evaluation and treatment should be started as early as possible, and treatment with mercaptopurine should be discontinued. Physicians should be attentive to symptoms of infection such as EBV and cytomegalovirus (CMV), as these are known triggers for MAS.</u></p><p><u>&nbsp;</u><strong><u>Metabolism and nutrition disorders</u></strong></p><p><u>Administration of purine analogues (azathioprine and mercaptopurine) may interfere with the niacin pathway, potentially leading to nicotinic acid deficiency/pellagra. Few cases have been reported with the use of azathioprine, especially in patients with IBD (Crohn&rsquo;s disease, colitis ulcerative). Diagnosis of pellagra should be considered in a patient presenting with localised pigmented rash (dermatitis); gastroenteritis (diarrhoea); and widespread neurologic deficits, including cognitive decline (dementia). Dose reduction or discontinuation of mercaptopurine treatment may not be required if appropriate medical care with niacin/nicotinamide supplementation is initiated. However, careful benefit-risk assessment is required on a case-by-case basis.</u></p><p><u>&nbsp;</u><strong><u>Infections </u></strong></p><p><u>Patients treated with 6-mercaptopurine alone or in combination with other immunosuppressive agents, including corticosteroids, have shown increased susceptibility to viral, fungal and bacterial infections, including severe or atypical infection, and viral reactivation. The infectious disease and complications may be more severe in these patients than in non-treated patients. </u></p><p><u>&nbsp;Prior exposure to or infection with varicella zoster virus should be taken into consideration prior to starting treatment. Local guidelines may be considered, including prophylactic therapy if necessary. Serologic testing prior to starting treatment should be considered with respect to hepatitis B. Local guidelines may be considered, including prophylactic therapy for cases which have been confirmed positive by serologic testing. Cases of neutropenic sepsis have been reported in patients receiving 6-mercaptopurine for ALL.&nbsp; </u></p><p><u>&nbsp;</u><strong><u>Patients with NUDT15 variant</u></strong></p><p><u>&nbsp;Patients with inherited mutated NUDT15 gene are at increased risk for severe 6-mercaptopurine toxicity, such as early leukopenia and alopecia, from conventional doses of thiopurine therapy. They generally require dose reduction, particularly those being NUDT15 variant homozygotes (see 4.2). The frequency of NUDT15 c.415C&gt;T has an ethnic variability of approximately 10 % in East Asians, 4 % in Hispanics, 0.2 % in Europeans and 0 % in Africans. In any case, close monitoring of blood counts is necessary. </u></p><p><strong><u>Paediatric population </u></strong></p><p><u>Cases of symptomatic hypoglycaemia have been reported in children with ALL receiving 6-mercaptopurine (see Section 4.8 Undesirable Effects). The majority of reported cases were in children under the age of six or with a low body mass index.</u></p><p><u>NUDT15 Mutation</u></p><p>Patients with inherited mutated NUDT15 gene are at increased risk for severe thiopurine toxicity, such as early leukopenia and alopecia, from conventional doses of thiopurine therapy and generally require substantial dose reduction. Patients of Asian ethnicity are particularly at risk, due to the increased frequency of the mutation in this population. The optimal starting dose for heterozygous or homozygous deficient patients has not been established. Genotypic and phenotypic testing of NUDT15 variants should be considered before initiating thiopurine therapy in all patients (including paediatric patients) to reduce the risk of thiopurine-related severe leukocytopenia and alopecia, especially in Asian populations (see section 5.2).</p><p>If the patient is infected during treatment appropriate measures should be taken, which may include antiviral therapy and supportive care.</p><p><u>Interactions</u></p><p>Patients treated with the xanthine oxidase inhibitors allopurinol, oxipurinol or thiopurinol, and 6- mercaptopurine should only receive 25 % of the usual dose of 6-mercaptopurine since allopurinol decreases the rate of catabolism of 6-mercaptopurine (see Section 4.2 Posology and method of administration and Section 4.5 Interaction with other medicinal products and other forms of interaction).</p><p><u>When oral anticoagulants are co-administered with 6-mercaptopurine, a reinforced monitoring of INR (International Normalised Ratio) is recommended (see section 4.5)</u></p><p><u>Excipients</u></p><p><u>Patients with rare hereditary problems of galactose intolerance, complete lactase deficiency or glucose-galactose malabsorption should not take this medicine.</u></p><p><u>&nbsp;TPMT Deficiency</u></p><p><u>There are individuals with an inherited deficiency of the enzyme thiopurine methyltransferase (TPMT) who may be unusually sensitive to the myelosuppressive effect of 6-mercaptopurine and prone to developing rapid bone marrow depression following the initiation of treatment with 6-mercaptopurine.&nbsp; This problem could be exacerbated by co-administration with medicinal products that inhibit TPMT, such as olsalazine, mesalazine or sulfazalazine.&nbsp; Also a possible association between decreased TPMT activity and secondary leukaemias and myelodysplasia has been reported in individuals receiving 6&ndash;mercaptopurine in combination with other cytotoxics (see Section 4.8 Undesirable effects).&nbsp; Approximately 0.3 % (1:300) of patients have little or no detectable enzyme activity. Approximately 10 % of patients have low or intermediate TPMT activity and 90 % of individuals have normal TPMT activity. There may also be a group of approximately 2 % who have very high TPMT activity. Some laboratories offer testing for TPMT deficiency, although these tests have not been shown to identify all patients at risk of severe toxicity.&nbsp; Therefore close monitoring of blood counts is still necessary.</u></p><p><u>Cross Resistance</u></p><p><u>Cross resistance usually exists between 6-mercaptopurine and 6-thioguanine.</u></p><p><u>&nbsp;Hypersensitivity </u></p><p><u>Patients suspected to have previously presented with a hypersensitivity reaction to 6-mercaptopurine should not be recommended to use its pro-drug azathioprine, unless the patient has been confirmed as hypersensitive to 6-mercaptopurine with allergological tests, and tested negative for azathioprine. As azathioprine is a pro-drug of 6-mercaptopurine, patients with a previous history of hypersensitivity to azathioprine must be assessed for hypersensitivity to 6-mercapopurine prior to initiating treatment.</u></p><p><u>Lesch-Nyhan syndrome </u></p><p><u>Limited evidence suggests that neither 6-mercaptopurine nor its pro-drug azathioprine are effective in patients with the rare inherited condition complete hypoxanthine-guanine-phosphoribosyltransferase deficiency (Lesch-Nyhan syndrome). The use of 6-mercaptopurine or azathioprine is not recommended in these patients.</u></p><p><u>UV exposure </u></p><p><u>Patients treated with 6-mercaptopurine are more sensitive to the sun. Exposure to sunlight and UV light should be limited, and patients should be recommended to wear protective clothing and to use a sunscreen with a high protection factor.</u></p><p><u>Safe handling of 6- mercaptopurine tablets &ndash; See section 6.6</u></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The administration of 6&ndash;mercaptopurine with food may decrease systemic exposure slightly. 6- mercaptopurine may be taken with food or on an empty stomach, but patients should standardise the method of administration to avoid large variability in exposure. The dose should not be taken with milk or dairy products since they contain xanthine oxidase, an enzyme which metabolises 6&ndash; mercaptopurine and might therefore lead to reduced plasma concentrations of mercaptopurine.</p><p><u>Effects of mercaptopurine on other medicinal products</u></p><p><u>Concomitant administration of yellow fever vaccine is contraindicated, due to the risk of fatal disease in immunocompromised patients (see section 4.3)</u></p><p><u>&nbsp;Vaccinations with other live organism vaccines are not recommended in immunocompromised individuals (see Section 4.4).</u></p><p><strong><u>Anticoagulants</u></strong></p><p><u>Inhibition of the anticoagulant effect of warfarin and acenocoumarol, when given with 6-mercaptopurine has been reported. Monitoring of the INR (International Normalised Ratio) value is recommended during concomitant administration with oral anticoagulants. </u></p><p><u>&nbsp;Cytotoxic agents may decrease the intestinal absorption of phenytoin. Careful monitoring of the phenytoin serum levels is recommended. It is possible that the levels of other anti-epileptic medicinal products may also be altered. Serum antiepileptic levels should be closely monitored during treatment with 6-mercaptopurine, making dose adjustments as necessary.</u></p><p>Effects of other medicinal products on 6-mercaptopurine</p><p><u>When allopurinol and 6-mercaptopurine are administered concomitantly it is essential that only a quarter of the usual dose of 6-mercaptopurine is given since allopurinol decreases the rate of metabolism of 6-mercaptopurine via xanthine oxidase. Also other xanthine oxidase inhibitors, such as febuxostat, may decrease the metabolism of mercaptopurine and concomitant administration is not recommended as data are insufficient to determine an adequate dose reduction.</u></p><p><u>As there is in vitro evidence that aminosalicylate derivatives (eg. olsalazine, mesalazine or sulfazalazine) inhibit the TPMT enzyme, which metabolises 6-mercaptopurine, they should be administered with caution to patients receiving concurrent 6-mercaptopurine therapy (see section 4.4).&rsquo;</u></p><p><strong>Methotrexate</strong></p><p>Methotrexate (20 mg/m<sup>2</sup> orally) increased 6-mercaptopurine AUC by approximately 31% and methotrexate (2 or 5 g/m<sup>2</sup> intravenously) increased 6-mercaptopurine AUC by 69 and 93%, respectively. Therefore, when 6-mercaptopurine is administered concomitantly with high dose methotrexate, the dose should be adjusted and white blood cell counts should be very closely monitored.</p><p><strong>Infliximab&nbsp;</strong></p><p>Interactions have been observed between azathioprine, a pro-drug of 6-mercaptopurine, and infliximab. Patients receiving ongoing azathioprine experienced transient increases in 6-TGN (6- thioguanine nucleotide, an active metabolite of azathioprine) levels and decreases in the mean leukocyte count in the initial weeks following infliximab infusion, which returned to previous levels after 3 months.</p><p><u>Therefore close monitoring of haematological parameters is necessary if Puri-nethol is administered with concomitant Infliximab therapy</u>.</p><p><strong><u>Ribavirin</u></strong></p><p><u>Ribavirin inhibits the enzyme, inosine monophosphate dehydrogenase (IMPDH), leading to a lower production of the active 6-thioguanine nucleotides. Severe myelosuppression has been reported following concomitant administration of a pro-drug of 6-mercaptopurine and ribavirin; therefore concomitant administration of ribavirin and 6-mercaptopurine is not advised (see section 4.4 Special warnings and precautions for use and section 5.2 Pharmacokinetic properties: metabolism).</u></p><p><u>&nbsp;Myelosuppressive agents</u></p><p><u>When 6-mercaptopurine is combined with other myelosuppressive agents caution should be used; dose reductions may be needed based on haematological monitoring (see section 4.4 Special warnings and precautions for use).</u></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong><u>Contraception in males and females</u></strong></p><p><u>Evidence of the teratogenicity of 6-mercaptopurine in humans is equivocal. Both sexually active men and women should use effective methods of contraception during treatment and for at least three months after receiving the last dose. Animal studies indicate embryotoxic and embryolethal effects (see section 5.3).</u></p><p><strong><u>Pregnancy</u></strong></p><p><u>6-mercaptopurine should not be given to patients who are pregnant or likely to become pregnant without careful assessment of risk versus benefit.</u></p><p><u>There have been reports of premature birth and low birth weight following maternal exposure to 6-mercaptopurine. There have also been reports of congenital abnormalities and spontaneous abortion following either maternal or paternal exposure. Multiple congenital abnormalities have been reported following maternal 6-mercatopurine treatment in combination with other chemotherapy agents.</u></p><p><u>A more recent epidemiological report suggests that there is no increased risk of preterm births, low birth weight at term, or congenital abnormalities in women exposed to mercaptopurine during pregnancy.</u></p><p><u>An increased incidence of miscarriage has been reported in women who received mercaptopurine in the first trimester of pregnancy. Adverse embryo-fetal findings, including miscarriage and stillbirth, have been reported in women who received mercaptopurine after the first trimester of pregnancy. Advise pregnant women of the potential risk to a fetus. Advise females of reproductive potential to use effective contraception during treatment with mercaptopurine and for 6 months after the last dose. Advise males with female partners of reproductive potential to use effective contraception during treatment with mercaptopurine and for 3 months after the last dose.</u></p><p><u>It is recommended that newborns of women exposed to mercaptopurine during pregnancy are monitored for haematological and immune system disturbances.</u><u> Verify the pregnancy status in females of reproductive potential prior to initiating mercaptopurine.</u></p><p><u>Breast-feeding</u></p><p><u>6-mercaptopurine has been identified in the colostrum and breast milk of women receiving azathioprine treatment and thus women receiving 6 mercaptopurine should not breast-feed</u></p><p><strong>Fertility</strong></p><p>The effect of 6&ndash;mercaptopurine therapy on human fertility is unknown <u>but there are reports of successful fatherhood/motherhood after receiving treatment during childhood or adolescence.</u></p><p>Transient <u>profound</u> oligospermia has been reported following exposure to 6&ndash;mercaptopurine <strong><u>in combination with</u> <u>corticosteroids.</u></strong></p><p>An increased incidence of miscarriage has been reported in women who received mercaptopurine in the first trimester of pregnancy. Adverse embryo-fetal findings, including miscarriage and stillbirth, have been reported in women who received mercaptopurine after the first trimester of pregnancy. Advise pregnant women of the potential risk to a fetus. Advise females of reproductive potential to use effective contraception during treatment with mercaptopurine and for 6 months after the last dose. Advise males with female partners of reproductive potential to use effective contraception during treatment with mercaptopurine and for 3 months after the last dose</p><p>It is recommended that newborns of women exposed to mercaptopurine during pregnancy are monitored for haematological and immune system disturbances. Verify the pregnancy status in females of reproductive potential prior to initiating mercaptopurine.</p><p><strong>Contraception in males and females</strong></p><p>Evidence of the teratogenicity of 6-mercaptopurine in humans is equivocal. Both sexually active men and women should use effective methods of contraception during treatment and for at least three months after receiving the last dose. Animal studies indicate embryotoxic and embryolethal effects (see section 5.3).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>There are no data on the effect of 6-mercaptopurine on driving performance or the ability to operate machinery. A detrimental effect on these activities cannot be predicted from the pharmacology of the medicinal product.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>&nbsp;Summary of the safety profile</p><p><u>The main side effect of treatment with 6 mercaptopurine is bone marrow suppression leading to leucopenia and thrombocytopenia.</u></p><p>For 6-mercaptopurine there is a lack of modern clinical documentation which can serve as support for accurately determining the frequency of undesirable effects. The frequency categories assigned to the adverse drug reactions below are estimates: for most reactions, suitable data for calculating incidence are not available. Undesirable effects may vary in their incidence depending on the dose received and also when given in combination with other therapeutic agents.</p><p><strong>Tabulated list of adverse reactions</strong></p><p><u>&nbsp;The following convention has been utilised for the classification of frequency: Very common &ge;1/10 </u></p><p><u>Common &ge;1/100 and &lt; 1/10 </u></p><p><u>Uncommon &ge;1/1000 and &lt;1/100 </u></p><p><u>Rare &ge;1/10,000 and &lt;1/1000 </u></p><p><u>Very rare &lt;1/10,000 </u></p><p><u>Not known (frequency cannot be estimated from the available data)</u></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td colspan="2" style="vertical-align:top"><p>Body System</p></td><td style="vertical-align:top"><p>Side effects</p></td></tr><tr><td style="vertical-align:top"><p>Infections and infestations</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Bacterial and viral infections, infections associated with neutropenia</p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p>Neoplasms Benign, Malignant</p><p>and&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Unspecified&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (including cysts and polyps)</p></td><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Neoplasms including lymphoproliferative</p><p>disorders, skin cancers (melanomas and non- melanomas), sarcomas (Kaposi&#39;s and non- Kaposi&#39;s) and uterine cervical cancer in situ (see section 4.4).</p></td></tr><tr><td style="vertical-align:top"><p>Very Rare</p></td><td style="vertical-align:top"><p>Secondary Leukaemia and myelodysplasia</p></td></tr><tr><td style="vertical-align:top"><p><u>Unknown</u></p></td><td style="vertical-align:top"><p><u>Hepatosplenic T-cell lymphoma in patients with inflammatory bowel disease (IBD) (an unlicensed indication) when used in combination with anti TNF agents (see Section 4.4.).</u></p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Blood and Lymphatic System Disorders</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Bone&nbsp;&nbsp; marrow&nbsp;&nbsp;&nbsp; suppression;&nbsp;&nbsp; leucopenia&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; and thrombocytopenia</p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Anaemia</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Immune System Disorders</p></td><td style="vertical-align:top"><p><u>Unknown</u></p></td><td style="vertical-align:top"><p>Hypersensitivity reactions with the following</p><p>manifestations have been reported: Arthralgia; skin rash; drug fever.</p></td></tr><tr><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Hypersensitivity reactions with the following manifestations have been reported: Facial oedema</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Metabolism&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; and&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; nutrition disorders</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Anorexia</p></td></tr><tr><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>Hypoglycaemia#</p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p>Gastrointestinal Disorders</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Nausea; vomiting; pancreatitis in the IBD</p><p>population (an unlicensed indication),<u> Stomatitis, diarrhoea.</u></p></td></tr><tr><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Oral ulceration; pancreatitis (in the licensed indications)</p></td></tr><tr><td style="vertical-align:top"><p>Very rare</p></td><td style="vertical-align:top"><p>Intestinal ulceration</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Hepatobiliary Disorders</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Biliary stasis; hepatotoxicity</p></td></tr><tr><td style="vertical-align:top"><p><u>Uncommon</u></p></td><td style="vertical-align:top"><p>Hepatic necrosis</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Skin and Subcutaneous Tissue</p><p>Disorders</p></td><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Alopecia</p></td></tr><tr><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>Photosensitivity <strong><u>reaction, Erythema nodosum</u></strong></p></td></tr><tr><td style="vertical-align:top"><p>Reproductive system and breast disorders</p></td><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Transient oligospermia</p></td></tr></tbody></table><p># In the paediatric population</p><p><strong>Description of selected adverse reactions:</strong></p><p><u>Hepatobiliary disorders</u></p><p>6- mercaptopurine is hepatotoxic in animals and man. The histological findings in man have shown hepatic necrosis and biliary stasis.</p><p>The incidence of hepatotoxicity varies considerably and can occur with any dose but more frequently when the recommended dose of 2.5 mg/kg bodyweight daily or 75 mg/m<sup>2</sup> body surface area per day is exceeded.</p><p>Monitoring of liver function tests may allow early detection of hepatotoxicity. Gamma glutamyl transferase (GGT) levels in plasma may be particularly predictive of withdraw al due to hepatotoxicity. This is usually reversible if 6-mercaptopurine therapy is stopped soon enough but fatal liver damage has occurred.</p><p><u>Please report adverse drug events to:</u></p><ul><li><strong>Saudi Arabia:</strong></li></ul><table border="1" cellspacing="1" cellpadding="1" style="width:500px"><tbody><tr><td><ul><li>The National Pharmacovigilance Centre (NPC):</li></ul><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Fax: +966-11-205-7662<br />-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;SFDA Call Center: 19999<br />-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;E-mail: npc.drug@sfda.gov.sa<br />-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Website: https://ade.sfda.gov.sa/</p></td></tr></tbody></table><p><strong>-</strong><strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Other GCC States:</strong></p><table border="1" cellspacing="1" cellpadding="1" style="width:500px"><tbody><tr><td>-&nbsp;&nbsp; &nbsp;Please contact the relevant competent authority.</td></tr></tbody></table><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Symptoms and signs</strong></p><p>Gastrointestinal effects, including nausea, vomiting and diarrhoea and anorexia may be early symptoms of overdose<s> </s>having occurred. The principal toxic effect is on the bone marrow, resulting in myelosuppression<em>. </em>Haematological toxicity is likely to be more profound with chronic overdose than with a single ingestion of 6-mercaptopurine. Liver dysfunction and gastroenteritis may also occur.</p><p>The risk of overdose<s> </s>is also increased when xanthine oxidase inhibitors are being given concomitantly with 6- mercaptopurine (see Section 4.5).</p><p><strong>&nbsp;<u>Management</u></strong></p><p>As there is no known antidote, blood counts should be closely monitored and general supportive measures, together with appropriate blood transfusion, instituted if necessary. Active measures (such as the use of activated charcoal <u>or gastric lavage</u>) may not be effective in the event of 6-mercaptopurine overdose unless the procedure can be undertaken within 60 minutes of ingestion.</p><p>Further management should be as clinically indicated or as recommended by the national poisons centre, where available.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: antineoplastic agents, antimetabolites, purine analogues, ATC Code: L01BB02</p><p><strong>Mechanism of action&nbsp;</strong></p><p>6-Mercaptopurine is sulphydryl analogue of the purine bases, adenine and hypoxanthine and acts as a cytotoxic antimetabolite.</p><p>6-Mercaptopurine is an inactive pro-drug which acts as a purine antagonist but requires cellular uptake and intracellular anabolism to thioguanine nucleotides for cytotoxicity. The 6-mercaptopurine metabolites inhibit <em>de novo </em>purine synthesis and purine nucleotide interconversions. The thioguanine nucleotides are also incorporated into nucleic acids and this contributes to the cytotoxic effects of the active substance.</p><p><u>Cross-resistance usually exists between 6-mercaptopurine and 6-thioguanine.</u></p><p><strong>Pharmacodynamic effects</strong></p><p>The cytotoxic effect of 6-mercaptopurine can be related to the levels of red blood cell 6- mercaptopurine derived thioguanine nucleotides, but not to the plasma 6-mercaptopurine concentration</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Absorption</strong></p><p>The bioavailability of oral 6-mercaptopurine shows considerable inter-individual variability, <u>which probably results from its first-pass metabolism`. </u>When administered <u>orally</u> at a dosage of 75 mg/m<sup>2</sup> to seven paediatric patients, the bioavailability averaged 16% of the administered dose, with a range of 5 to 37%.</p><p>After oral administration of 6-mercaptopurine 75 mg/m<sup>2</sup> to 14 children with acute lymphoblastic leukaemia, the mean Cmax was 0.89&micro;M, with a range of 0.29 - 1.82&micro;M and Tmax was 2.2 hours with a range of 0.5 - 4 hours.</p><p>The mean relative bioavailability of 6-mercaptopurine was approximately 26 % lower following administration with food and milk compared to an overnight fast. 6-mercaptopurine is not stable in milk due to the presence of xanthine oxidase (30 % degradation within 30 minutes) (see Section 4.2 Posology and method of administration).</p><p><strong>Distribution</strong></p><p>Concentrations of 6-mercaptopurine in cerebrospinal fluid (CSF) are low or negligible after IV or oral administration (CSF: plasma ratios of 0.05 to 0.27). Concentrations in the CSF are higher after intrathecal administration.</p><p><strong>Biotransformation</strong></p><p><u>The intracellular anabolism of 6-merpactopurine is catalysed by several enzymes to eventually form 6-thioguanine nucleotides (TGNs), but a variety of intermediary TGNs are formed en route to the TGNs. The first step is catalysed by hypoxanthine-guanine phosphoribosyl transferase yielding thioinosine monophosphate (TIMP). 6-mercaptopurine is also subject to S-methylation by the enzyme thiopurine S-methyltransferase (TPMT), yielding methylmercaptopurine, which is inactive. However, TPMT also catalyses the S-methylation of the principle nucleotide metabolite, TIMP, to form methylthioinosine monophosphate (mTIMP). Both TIMP and mTIMP are inhibitors of phosphoribosyl pyrophosphate amidotransferase, an enzyme which is important in de novo purine synthesis. Xanthine oxidase is the main catabolic enzyme and it converts the 6-mercaptopurine into the inactive metabolite, 6-thiouric acid. This is excreted in the urine. Approximately 7% of an oral dose is excreted as unchanged 6-mercaptopurine within 12 hours after administration.</u></p><p>There is evidence that polymorphisms in the genes encoding the different enzyme systems involved with metabolism of 6-mercaptopurine may predict adverse drug reactions to 6-mercaptopurine therapy. For example, individuals with TPMT deficiency develop very high cytotoxic thioguanine nucleotide concentrations (see Section 4.4).</p><p><u>Recent studies indicate that a strong association exists between the NUDT15 variant NUDT15</u> <u>c.415C&gt;T [p.Arg139Cys] (also known as NUDT15 R139C [rs116855232]), which is thought to lead</u> <u>to a loss of function of the NUDT15 enzyme, and thiopurine-mediated toxicity such as leukopenia and</u> <u>alopecia. The frequency of NUDT15 c.415C&gt;T has an ethnic variability of 9.8 % in East Asians, 3.9</u></p><p><u>% in Hispanics, 0.2 % in Europeans and 0.0 % in Africans, indicating an increased risk for the Asian</u> <u>population. Patients who are NUDT15 variant homozygotes (NUDT15 T risk alleles) are at an</u> <u>excessive risk of thiopurine toxicity compared with the C homozygotes.</u></p><p><u>Reduced thiopurine doses for patients who carry the NUDT15 variants may decrease their risk of</u> <u>toxicity. Therefore, genotypic analysis determining NUDT15 genotype should be determined for all</u> <u>patients, including paediatric patients, prior to initiating thiopurine treatment (see section 4.2). The</u> <u>prescribing physician is advised to establish whether dose reduction is required based on patient</u> <u>response to treatment as well as their genetic profile.</u></p><p><u>Patients with variants in both the NUDT15 and TPMT enzymes are significantly less tolerant of</u> <u>thiopurines than those with risk alleles in only one of these two genes.</u></p><p><u>The precise mechanism of NUDT15-associated thiopurine-related toxicity is not understood.</u></p><p><strong>Elimination</strong></p><p><u>The elimination half-life of 6-mercaptopurine is 90 &plusmn; 30 minutes, but the active metabolites have a longer half-life (approximately 5 hours) than the parent compound. The apparent body clearance is 4832 &plusmn; 2562 ml/min/m2. There is low entry of 6-mercaptopurine into the cerebrospinal fluid. The main route of elimination for 6-mercaptopurine is by metabolism.</u></p><p>In a study with 22 adult patients the mean 6-mercaptopurine clearance and half-life after IV infusion was 864 mL/min/m<sup>2</sup> and 0.9 hours respectively. The mean renal clearance reported in 16 of these patients was 191 mL/min/m<sup>2</sup>. Only about 20 % of the dose was excreted in the urine as intact <u>drug</u> medicinal product after IV administration. In a study with 7 children patients the mean 6- mercaptopurine clearance and half-life after IV infusion was 719 (+/-610) ml/min/m<sup>2</sup> and 0.9 (+/-0.3) hours respectively.</p><p><strong><u>Special patient populations</u></strong></p><ul><li><strong>&nbsp;</strong>Elderly</li></ul><p>No specific studies have been carried out in the elderly (see Section 4.2 Posology and method of administration).</p><ul><li>Renal impairment</li></ul><p>Studies with a pro-drug of 6-mercaptopurine have shown no difference in 6-mercaptourine pharmacokinetics in uremic patients compared to renal transplant patients. Since little is known about the active metabolites of 6-mercaptopurine in renal impairment (see Section 4.2 Posology and method of administration).</p><p>6- mercaptopurine and/or its metabolites are eliminated by haemodialysis, with approximately 45 % of radioactive metabolites eliminated during dialysis of 8 hours.</p><ul><li>Hepatic impairment</li></ul><p>A study with a pro-drug of 6-mercaptopurine was performed in three groups of renal transplant patients: those without liver disease, those with hepatic impairment (but no cirrhosis) and those with hepatic impairment and cirrhosis. The study demonstrated that 6-mercaptopurine exposure was 1.6 times higher in patients with hepatic impairment (but no cirrhosis) and 6 times higher in patients with hepatic impairment and cirrhosis, compared to patients without liver disease (see Section 4.2 Posology and method of administration).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Genotoxicity</u></p><p><u>6-mercaptopurine, in common with other antimetabolites, is mutagenic and causes chromosomal aberrations in vitro and in vivo in mice and rats.</u></p><p><u>&nbsp;Carcinogenicity</u></p><p><u>Given its genotoxic potential, 6-mercaptopurine is potentially carcinogenic.</u></p><p><u>&nbsp;Teratogenicity</u></p><p><u>6-mercaptopurine causes embryolethality and severe teratogenic effects in the mouse, rat, hamster and rabbit at doses that are non-toxic to the mother. In all species, the degree of embryotoxicity and the type of malformations are dependent on the dose and stage of the gestation at the time of administration</u></p><p><strong>&nbsp;</strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Lactose monohydrate</p><p>Maize Starch</p><p>Modified Maize Starch</p><p>Stearic Acid</p><p>Magnesium Stearate</p><p>Purified Water</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>None known</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                60 months
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Do not store above 30&deg;C. Protect from light and Keep dry.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Amber glass bottles with child resistant high density polyethylene closures with induction heat seal liners.</p><p>Pack size: 25 tablets</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>It is recommended that 6-mercaptopurine tablets should be handled following the prevailing local recommendations and/or regulations for the handling and disposal of cytotoxic agents.</p><p><strong>Handling</strong>:</p><ul><li>&nbsp;Puri-nethol is a cytotoxic drug. Considered as potentially carcinogenic</li><li>In healthcare settings, use designated area for medication storage and restrict access to only authorized personal</li><li>To minimize the risk of dermal exposure, wear chemotherapy gloves and sleeve covers when handling Puri-Nethol. This includes all handling activities in clinical settings, pharmacies, storerooms and home healthcare settings, including receiving, unpacking and, and storing within a facility.</li><li>For transportation of intact tablet within the facility, wear single chemotherapy gloves and place in double bag or in a sealed container.</li><li>The tablets should not be divided, broken or crushed. This might produce powder that can contaminate workplace surfaces.</li><li>Caution should be observed in handling broken or crushed tablets; wear double chemotherapy gloves and place in double bag or in a sealed container. Avoid direct contact with skin or mucous membranes. If such contact occurs, wash thoroughly with soap and water, rinse eyes thoroughly with sterile water, or plain water if sterile water is unavailable.</li><li>When manipulations are necessary such as compounding, crushing, cutting, or splitting; should be performed within a ventilated engineering enclosure and/ or augment the control of generated aerosols using supplementary controls such as glove bags or pill pouches that contain the hazardous drug during and after the crushing process.</li><li>Wear double chemotherapy gloves, protective gown and sleeve covers. Add eye/face protection and respiratory protection [N95] if compounding is done outside of the ventilated engineering control. Hair and shoe covers should be worn.</li><li>When clinically appropriate, add liquid or moist products to crushed hazardous drug product as soon as possible after crushing, to avoid the potential of subsequent aerosol dissemination.</li><li>For medication administration, wear single chemotherapy gloves with intact and coated tablets and double chemotherapy gloves with cut or crushed tablets. Add eye and face protection if there is the potential to contact vomit or if patient may resist or is pre-disposed to spitting out.</li><li>Personnel who are pregnant should avoid exposure to crushed or broken coated tablets.</li></ul><p>Disposal</p><ul><li>Wear double chemotherapy gloves and protective gown for any disposal or cleaning activity of medication contaminated waste.</li><li>Avoid creating dusts. Place in sealed bags for disposal. Use caution when closing bags as pushing waste down may force hazardous drug dusts up into the user&rsquo;s face.</li><li>For disposal of drugs and metabolites in body fluids, wear chemotherapy gloves and protective gown. Fold soft materials (sheets, hygiene care products) inward to prevent leakage and place in sealed bags.</li><li>In case of spill, limit access to area, use wet wiping method (absorbent pads for liquid spills). Place in sealed bags for disposal. Disinfection, deactivation or decontamination agents may be necessary.</li><li>Any unused medicinal product or waste material should be disposed of in accordance with local requirements.</li></ul>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Aspen Pharma Trading Limited 
3016 Lake Drive,
Citywest Business Campus, 
Dublin 24,
Ireland

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                July/2023
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>